Overview
Gyrin1 is a protein inhibitor targeting the DNA gyrase subunit A (GyrA) in bacteria, essential for regulating DNA supercoiling during replication and transcription. Initially identified in phage systems, it has become a valuable tool in microbiological research and antibiotic discovery. Unlike broad-spectrum inhibitors, Gyrin1 exhibits specificity for GyrA, making it useful for mechanistic studies of bacterial topoisomerases. Its modular structure allows for engineering variants with altered binding affinities, expanding its utility in synthetic biology.
Physical and Chemical Properties
As a protein, Gyrin1’s properties depend on its amino acid sequence and post-translational modifications. Typical preparations are lyophilized powders or buffered solutions with pH stability between 6.0–8.0. Its molecular weight ranges 10–15 kDa, verified via SDS-PAGE or mass spectrometry. Solubility is optimal in mild buffers like PBS or Tris-HCl. Aggregation may occur at high concentrations (>1 mg/mL), requiring additives (e.g., glycerol) for stabilization. Circular dichroism studies confirm α-helical domains critical for GyrA binding.
Main Applications
Gyrin1 is primarily used in academic and industrial labs to investigate DNA gyrase mechanics, particularly in Gram-negative bacteria like E. coli. It serves as a positive control in assays screening for novel gyrase inhibitors. Pharmaceutical researchers explore its potential as a scaffold for designing narrow-spectrum antibiotics, leveraging its specificity to reduce off-target effects. Recent studies also apply Gyrin1 in CRISPR-Cas9 systems to modulate DNA topology during gene editing.
Safety and Storage
While Gyrin1 poses minimal toxicity at standard research doses, lab handling requires gloves and eye protection. Avoid inhalation of lyophilized powder; reconstitute in a fume hood if volatile solvents are used. For storage, aliquot solutions to prevent degradation and freeze at -20°C or below. Include protease inhibitors (e.g., PMSF) for long-term stability. Discard discolored or precipitated samples, as these indicate protein denaturation.
B2B Procurement Guide
When sourcing Gyrin1, prioritize vendors providing certificates of analysis (CoA) with purity (>95%) and endotoxin levels (<1 EU/μg). Recombinant versions (e.g., E. coli-expressed) offer batch-to-batch consistency versus native purification. Bulk buyers should negotiate pricing for quantities above 10 mg, with discounts often reaching 15–20%. Consider suppliers offering custom modifications (e.g., fluorescent labeling) for specialized applications. Lead times vary; plan for 2–4 weeks for synthesized variants.